Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache

Jill C. Rau, Edita Navratilova, Janice Oyarzo, Kirk W. Johnson, Sheena K. Aurora, Todd J. Schwedt, David W. Dodick, Frank Porreca

Research output: Contribution to journalArticle

Abstract

Background: Medication overuse is a significant issue that complicates the treatment of headache disorders. The most effective medications for the acute treatment of migraine all have the capacity to induce medication overuse headache (MOH). Novel acute migraine-specific treatments are being developed. However, because the mechanism(s) underlying medication overuse headache are not well understood, it is difficult to predict whether any particular acute medication will induce MOH in susceptible individuals. LY573144 (lasmiditan), a 5-HT1F receptor agonist, has recently been shown to be effective in the acute treatment of migraine in phase 3 trials. The aim of this study is to determine whether frequent administration of lasmiditan induces behaviors consistent with MOH in a pre-clinical rat model. Methods: Sprague Dawley rats were administered six doses of lasmiditan (10 mg/kg), sumatriptan (10 mg/kg), or sterile water orally over 2 weeks and cutaneous allodynia was evaluated regularly in the periorbital and hindpaw regions using von Frey filaments. Testing continued until mechanosensitivity returned to baseline levels. Rats were then submitted to bright light stress (BLS) or nitric oxide (NO) donor administration and were again evaluated for cutaneous allodynia in the periorbital and hindpaw regions hourly for 5 hours. Results: Both lasmiditan and sumatriptan exhibited comparable levels of drug-induced cutaneous allodynia in both the periorbital and hindpaw regions, which resolved after cessation of drug administration. Both lasmiditan and sumatriptan pre-treatment resulted in cutaneous allodynia that was evoked by either BLS or NO donor. Conclusions: In a pre-clinical rat model of MOH, oral lasmiditan, like sumatriptan, induced acute transient cutaneous allodynia in the periorbital and hindpaw regions that after resolution could be re-evoked by putative migraine triggers. These results suggest that lasmiditan has the capacity to induce MOH through persistent latent peripheral and central sensitization mechanisms.

Original languageEnglish (US)
Pages (from-to)903-912
Number of pages10
JournalCephalalgia
Volume40
Issue number9
DOIs
StatePublished - Aug 1 2020

Keywords

  • Pain
  • allodynia
  • lasmiditan
  • migraine
  • stress
  • sumatriptan

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache'. Together they form a unique fingerprint.

  • Cite this

    Rau, J. C., Navratilova, E., Oyarzo, J., Johnson, K. W., Aurora, S. K., Schwedt, T. J., Dodick, D. W., & Porreca, F. (2020). Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. Cephalalgia, 40(9), 903-912. https://doi.org/10.1177/0333102420920006